Immix Biopharma Inc (IMMX) News

IMMX under $3

Watch out when the insiders buy more, it’l pop to 5/6 again, these 2’s are a easy double

These are cheap now, buy em up folks $$$$$$$

Been adding this, updates should commence soon $$$$$$

Interesting dip this had, loaded more

Dropping like a rock, 2$ is a buy barring any bad news that leaked out

IMMX 10Q due 3/26
Next day settlement 5/28 per SEC mandate

Stock has been crushed waiting to see if 2.50 holds watching

Great time to add more

Insiders did not flip any shares! Very good hold here

Added again

Added 5.80-5.90

Boom

I think 4 per share is go time!

We will see $10 plus

Back to $5- highest mark in 2 years.. IPO price..

$IMMX current valuation with everything the way it is. should be 300-500 m ..
as far as technicals.. great current chart..
an increase of volume should propel this to 5 (which was the IPO price) and an test of the 7.5-9 area before end of year..
good luck to all.

I see this $10

Careful,dilution could happen anytime here. We sold out completely. Will watch this for awhile

Boom!

Creeping up. I see us at $5 plus

Might add 2.15 area

Nothing but sells

Under 3 again it seems, insiders selling off?? Again! Probably in kahoots with hedge fund managers. This should be well over 4$ an it cannot hold, red flag again, we’l see

Next big bio here, huge upside possible. Adding here again to the stash

Thanks

NEWS Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff

100% (4/4) overall response rate and 75% (3/4) complete response rate observed in t(11;14) relapsed/refractory AL Amyloidosis

Best responder duration of response was 19.2 months with response ongoing; median follow-up of 7.3 months (range: 2.5 – 16.5 months) as of the data cutoff date of September 20, 2023

ImmixBio plans to submit a BLA for FDA approval in AL Amyloidosis once 40 patients are treated with NXC-201

The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX ® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.

“There are no approved drugs for relapsed/refractory AL Amyloidosis,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action. Additionally, as a one-time treatment, NXC-201 would present an attractive alternative to multi-drug combination, long-term daily or weekly regimens for relapsed/refractory AL amyloidosis patients.”

“Currently, AL Amyloidosis treatment involves repeat dosing and weekly distant travel to academic medical centers,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. “One-time treatment with NXC-201 could fill the void for relapsed/refractory AL Amyloidosis, where there are no therapies approved today, while restoring quality of life.”

Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “NXC-201’s uniquely favorable CAR-T tolerability profile and an apparent ability to clear disease-causing amyloid chains from the body within ~30 days could make it particularly suitable for treatment in a potential outpatient setting.”

Boom!

kind of a Perfect Storm..
-great chart- 52 week high, with B/O on daily and weekly
-increased volume
-strong insider buying
-very low float and market cap..
-very strong trials on FDA Orphan drug designated products. .

Highest volume in months. Glad to see it

Thanks

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma




Yahoo Finance

Yahoo Finance

Sign in

?

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Immix Biopharma, Inc.

Mon, Oct 2, 2023, 5:06 AM PDT11 min read



IMMX+20.91%


Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma



Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off

90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapy

Class-Leading Response Rate in BCMA-exposed patients (frequently excluded from BCMA CAR-T clinical trials) has the potential to meet an important market need

ImmixBio plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201

The expected primary endpoints for NXC-201 in relapsed/refractory multiple myeloma are overall response rate and duration of response

great Nexcella results.
breakout on daily and weekly chart.
low float and increased volume..
making a beeline back to ipo price of 5 and then ath 8.5

Did something leak?

Impressive volume

71k on the ask

What the…

Expected better volume after yesterday

.20 from highs

Will it go to 2$ area again, triple down here

Now 15% yikes

Can’t even find a buyer at -10%

73% insider owned

Adding to the stash, buyout candidate here, looming for 15! $$$$$$

low volume Friday..
Still near zero out side buyers and retail..
all the volume has been from within..
once the volume comes..

Down 10%

3.65 new 52 week high and still building.. LOW FLOAT

most of buying has been insiders and friends.. wait till everyone else figures this out.

52 week high ..volume building
3.40

NEWS! U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for:

7 years of U.S. market exclusivity after approval

Tax credits for qualified clinical testing

Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug)

The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research

LOS ANGELES, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) designation for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201, a next generation CAR-T cell therapy, is currently being evaluated in a Phase 1b/2a clinical trial NEXICART-1 (NCT04720313).

The FDA’s Office of Orphan Products Development grants orphan designation status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to 7 years of market exclusivity in the U.S. upon regulatory approval.

“We are pleased to receive FDA’s orphan drug designation in AL amyloidosis for NXC-201, the only clinical-stage CAR-T cell therapy in development for AL amyloidosis,” said Ilya Rachman, MD PhD, Immix Biopharma Chief Executive Officer, adding, “We are thrilled to potentially expand therapeutic options for relapsed and refractory AL amyloidosis patients, where we have observed to date in our NXC-201 clinical trials a 100% hematologic response rate and demonstrated organ responses in patient hearts, livers and kidneys, for AL amyloidosis patients who received a median of 6 earlier treatments that previously failed to halt the disease.” Gabriel Morris, Immix Biopharma Chief Financial Officer, added, “We believe one-time treatment NXC-201 could offer AL amyloidosis patients a convenient therapeutic option.”

Strong Board of Directors Buying in past few weeks. + FDA orpah Drug designations + Great chart

looks to get to IPO price of 5$ soon...

Beautiful chart with breakout past $3 imminent.
Still think the stock is super cheap.

Watching

An load more $$$$$